

MAR 2 2001

TECH CENTER 1600/2900

PATENT

Express Mail Label No: EL728729076US

Date of Deposit: March 19, 2001

Response under 37 CFR § 1.116

--EXPEDITED PROCEDURE--

Examining Group 1600

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Russell, et al.
U.S. Serial No. 09/043,665
Filed (U.S.): October 5, 1998

Group: 1632

Entitled: Materials and Methods Relating to the
Transfer of Nucleic Acid Into
Quiescent Cells

Examiner: R. Shukla Ph.D

Attorney Docket No.: 4219/1340 (formerly 3789/81421)

Commissioner for Patents and Trademarks
Washington, D.C. 20231

DECLARATION OF COLIN M. CASIMIR UNDER 37 C.F.R. 1.132

I, Colin M. Casimir, hereby declare that:

1. I am a co-inventor on the above-noted U.S. patent application; I received a Ph.D. from The University of Glasgow in 1981. I am currently a Senior Lecturer in the Department of Haematology at the Imperial College School of Medicine, in London, U.K. I perform basic research in the area of gene therapy, particularly for immunodeficiency. My research publications relating to gene therapy include the following: Thrasher, A., Chetty, M., Casimir, C.M., Segal, A.W. Restoration of superoxide generation to a chronic granulomatous disease derived B cell line by retrovirus mediated gene transfer. *Blood* 80,1125-1129 (1992); Thrasher, A., Segal, A.W., Casimir, C. M. Chronic Granulomatous Disease: Towards Gene Therapy. *Immunodeficiency* 4, 327-333 (1993); Povey J, Weeratunge N, Marden C, Sehgal A, Thrasher A, Casimir C. Enhanced Retroviral Transduction of 5-FU-Resistant Human Bone Marrow (Stem) Cells Using a Genetically Modified Packaging Cell Line. *Blood*